TABLE 1.

Demographic, clinicopathologic, and molecular characteristics

	LUSI + (n = 223)		LUSI − (n = 258)		p
	N	%	N	%
Age (years)					0.43
Mean ± standard deviation	62.5 ± 11.7		63.4 ± 11.3
BMI (kg/m2)					0.18
Mean ± standard deviation	36.0 ± 11.0		34.4 ± 9.6
Race					0.62
White	199	89.2	227	87.9
Black	24	10.8	30	11.7
Other/not specified	0	0	1	0.4
Stage					<0.001
IA	24	10.7	88	34.1
IB	101	45.3	121	46.9
IC	49	22	46	17.8
II	49	22	3	1.2
Grade					0.51
1	124	55.6	156	53
2	67	30.1	74	33.7
3	31	13.9	28	13.3
Not evaluable	1	0.4	0	0
Adjuvant treatment					0.32
Yes	48	21.5	47	18.2
No	172	77.2	210	81.4
Not specified	3	1.3	1	0.4
LVSI					<0.01
Present	67	30.0	42	16.3
Absent	156	70.0	215	83.3
Not specified	0	0	1	0.4
MSI statusa					0.36
Neg/low	127	70.2	116	64.1
High	53	29.3	61	33.7
No data	1	0.5	4	2.2

BMI body mass index, LUSI lower uterine segment involvement, MSI microsatellite instability, LVSI lymphovascular space involvement

^aMSI data available for 357 tumors